<DOC>
	<DOCNO>NCT00306995</DOCNO>
	<brief_summary>Influenza pandemic cause virus possess Hemagglutinin molecule population lack immunity . If virus pathogenic human demonstrate ability transmit person person , result global outbreak disease affect high percentage individual short period time likely cause substantially increase mortality morbidity country world . Recently , purely avian influenza virus , include H5N1 , H9N2 H7N7 subtypes , directly transmit human , raise concern possibility new influenza pandemic among world 's immunologically naive population . In order face kind situation , pandemic influenza vaccine develop .</brief_summary>
	<brief_title>Safety Study Pandemic Candidate Influenza Vaccines Elderly Population</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe comply requirement protocol A male female age 60 year time vaccination . Written inform consent obtain subject . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede administration study vaccine , plan use study period . Participation earlier study candidate pandemic H9N2 vaccine . Acute disease time enrolment . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality History allergic disease reaction likely exacerbate component vaccine . Drug and/or alcohol dependency .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prophylaxis pandemic influenza</keyword>
</DOC>